PA8506301A1 - Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida - Google Patents
Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituidaInfo
- Publication number
- PA8506301A1 PA8506301A1 PA20008506301A PA8506301A PA8506301A1 PA 8506301 A1 PA8506301 A1 PA 8506301A1 PA 20008506301 A PA20008506301 A PA 20008506301A PA 8506301 A PA8506301 A PA 8506301A PA 8506301 A1 PA8506301 A1 PA 8506301A1
- Authority
- PA
- Panama
- Prior art keywords
- crystal
- carboxamino
- tetrahydroquinoline
- replaced
- crystals
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
- C07D215/42—Nitrogen atoms attached in position 4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Quinoline Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Cephalosporin Compounds (AREA)
Abstract
SE DESCRIBEN FORMAS CRISTALINAS DE UN INHIBIDOR DE CETP, PROCEDIMIENTOS PARA PREPARAR LOS CRISTALES, PROCEDIMIENTOS DE USO DE LOS CRISTALES Y COMPOSICIONES FARMACEÚTICAS QUE CONTIENEN LOS CRISTALES.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16805199P | 1999-11-30 | 1999-11-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
PA8506301A1 true PA8506301A1 (es) | 2002-08-26 |
Family
ID=22609901
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PA20008506301A PA8506301A1 (es) | 1999-11-30 | 2000-11-13 | Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida |
Country Status (28)
Country | Link |
---|---|
EP (1) | EP1246804A1 (es) |
JP (1) | JP2003515592A (es) |
KR (1) | KR20020058057A (es) |
CN (1) | CN1402711A (es) |
AP (1) | AP2002002531A0 (es) |
AU (1) | AU1048801A (es) |
BG (1) | BG106854A (es) |
BR (1) | BR0015836A (es) |
CA (1) | CA2392979A1 (es) |
CO (1) | CO5271716A1 (es) |
EA (1) | EA200200510A1 (es) |
EC (1) | ECSP003792A (es) |
EE (1) | EE200200277A (es) |
GT (1) | GT200000199A (es) |
HU (1) | HUP0203521A2 (es) |
IL (1) | IL149097A0 (es) |
IS (1) | IS6338A (es) |
MA (1) | MA26845A1 (es) |
MX (1) | MXPA02005354A (es) |
NO (1) | NO20022558L (es) |
OA (1) | OA12099A (es) |
PA (1) | PA8506301A1 (es) |
PE (1) | PE20010904A1 (es) |
PL (1) | PL355892A1 (es) |
TN (1) | TNSN00231A1 (es) |
TR (1) | TR200201446T2 (es) |
UY (1) | UY26454A1 (es) |
WO (1) | WO2001040190A1 (es) |
Families Citing this family (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7115279B2 (en) | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CZ20033341A3 (cs) * | 2001-06-21 | 2004-10-13 | Pfizeráproductsáinc | Samoemulgující se kompozice inhibitorů přenosového proteinu cholesterylesteru |
GT200200170A (es) | 2001-09-28 | 2003-05-23 | Preparacion de inhibidor de cetp anhidro | |
MXPA04007438A (es) | 2002-02-01 | 2004-10-11 | Pfizer Prod Inc | Composiciones farmaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
EP1920766B1 (en) * | 2002-02-01 | 2017-08-23 | Bend Research, Inc | Pharmaceutical compositions of amorphous dispersions of drugs and lipophilic microphase-forming materials |
EP1469833B1 (en) * | 2002-02-01 | 2021-05-19 | Bend Research, Inc. | Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus |
PT1533292E (pt) | 2002-08-30 | 2007-05-31 | Japan Tobacco Inc | Compostos de dibenzilamina e sua utilização farmacêutica. |
JP2006508077A (ja) | 2002-10-04 | 2006-03-09 | ミレニアム・ファーマシューティカルズ・インコーポレイテッド | 炎症疾患を治療するためのpgd2レセプタアンタゴニスト |
US7504508B2 (en) | 2002-10-04 | 2009-03-17 | Millennium Pharmaceuticals, Inc. | PGD2 receptor antagonists for the treatment of inflammatory diseases |
MXPA05005813A (es) | 2002-12-20 | 2005-12-12 | Pfizer Prod Inc | Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa. |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
EP1622872A1 (en) * | 2003-03-28 | 2006-02-08 | Pfizer Products Inc. | 1,2,4-substituerte 1,2,3,4-tetrahydro-and 1,2 dihydro-quinoline and 1,2,3,4-tetrahydro-quinoxaline derivatives as cetp inhibitors for the treatment of atherosclerosis and obesity |
EP1653927B1 (en) | 2003-08-04 | 2012-01-11 | Bend Research, Inc. | Pharmaceutical compositions of adsorbates of amorphous drugs and lipophilic microphase-forming materials |
CN1863778A (zh) | 2003-10-08 | 2006-11-15 | 伊莱利利公司 | 用于治疗血脂异常的化合物及方法 |
CA2562082C (en) * | 2004-04-13 | 2013-06-25 | Merck & Co., Inc. | Cetp inhibitors for the treatment and prevention of atherosclerosis |
JP2008504266A (ja) * | 2004-06-24 | 2008-02-14 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物及び方法 |
WO2006033004A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds as cetp inhibitors |
WO2006033001A1 (en) * | 2004-09-23 | 2006-03-30 | Pfizer Products Inc. | Quinoline compounds |
RU2007135224A (ru) | 2005-02-24 | 2009-03-27 | Милленниум Фармасьютикалз, Инк. (Us) | Антагонисты рецептора pgd2 для лечения воспалительных заболеваний |
WO2006098394A1 (ja) * | 2005-03-14 | 2006-09-21 | Japan Tobacco Inc. | 脂質吸収抑制方法および脂質吸収抑制剤 |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
TW200901959A (en) | 2007-03-09 | 2009-01-16 | Indigene Pharmaceuticals Inc | Combination of metformin R-(+) lipoate and antihyperlipidemic agents for the treatment of diabetic hyperglycemia and diabetic complications |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
US20110243940A1 (en) | 2008-12-16 | 2011-10-06 | Schering Corporation | Bicyclic pyranone derivatives and methods of use thereof |
AR077208A1 (es) | 2009-06-30 | 2011-08-10 | Lilly Co Eli | Derivados del acido trans-4-[[(5s)-5-[[[3,5-bis(trifluorometil) fenil] metil] (2-metil-2h-tetrazol-5-il) amino) -2,3,4,5-tetrahidro-7,9-dimetil-1h-1-benzazepin-1-il) metil)-ciclohexancarboxilico y sus formas cristalinas, composiciones farmaceuticas que los comprenden, su uso para preparar un medicam |
KR102456013B1 (ko) | 2014-07-30 | 2022-10-18 | 에프. 호프만-라 로슈 아게 | 고밀도 지질단백질(hdl)-상승 제제 또는 hdl-모방 제제에 의한 치료법에 대한 반응성을 예측하기 위한 유전 표지 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5231102A (en) * | 1989-03-08 | 1993-07-27 | Merck Sharp & Dohme, Ltd. | Tetrahydroquinoline derivatives useful for neurodegenerative disorders |
WO1998033775A1 (en) * | 1997-02-03 | 1998-08-06 | American Home Products Corporation | 2-substituted-1-acyl-1,2-dihydroquinoline derivatives to increase hdl-cholesterol level |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
-
2000
- 2000-11-09 CO CO00085285A patent/CO5271716A1/es unknown
- 2000-11-13 PA PA20008506301A patent/PA8506301A1/es unknown
- 2000-11-14 PL PL00355892A patent/PL355892A1/xx not_active Application Discontinuation
- 2000-11-14 HU HU0203521A patent/HUP0203521A2/hu unknown
- 2000-11-14 MX MXPA02005354A patent/MXPA02005354A/es unknown
- 2000-11-14 KR KR1020027006914A patent/KR20020058057A/ko not_active Application Discontinuation
- 2000-11-14 IL IL14909700A patent/IL149097A0/xx unknown
- 2000-11-14 CN CN00816463A patent/CN1402711A/zh active Pending
- 2000-11-14 WO PCT/IB2000/001650 patent/WO2001040190A1/en not_active Application Discontinuation
- 2000-11-14 CA CA002392979A patent/CA2392979A1/en not_active Abandoned
- 2000-11-14 AU AU10488/01A patent/AU1048801A/en not_active Abandoned
- 2000-11-14 OA OA1200200158A patent/OA12099A/en unknown
- 2000-11-14 TR TR2002/01446T patent/TR200201446T2/xx unknown
- 2000-11-14 EA EA200200510A patent/EA200200510A1/ru unknown
- 2000-11-14 EP EP00971662A patent/EP1246804A1/en not_active Withdrawn
- 2000-11-14 AP APAP/P/2002/002531A patent/AP2002002531A0/en unknown
- 2000-11-14 EE EEP200200277A patent/EE200200277A/xx unknown
- 2000-11-14 BR BR0015836-4A patent/BR0015836A/pt not_active IP Right Cessation
- 2000-11-14 JP JP2001541875A patent/JP2003515592A/ja active Pending
- 2000-11-28 PE PE2000001267A patent/PE20010904A1/es not_active Application Discontinuation
- 2000-11-28 UY UY26454A patent/UY26454A1/es not_active Application Discontinuation
- 2000-11-29 EC EC2000003792A patent/ECSP003792A/es unknown
- 2000-11-29 GT GT200000199A patent/GT200000199A/es unknown
- 2000-11-29 TN TNTNSN00231A patent/TNSN00231A1/fr unknown
-
2002
- 2002-04-12 IS IS6338A patent/IS6338A/is unknown
- 2002-05-27 MA MA26653A patent/MA26845A1/fr unknown
- 2002-05-29 NO NO20022558A patent/NO20022558L/no not_active Application Discontinuation
- 2002-06-20 BG BG106854A patent/BG106854A/bg unknown
Also Published As
Publication number | Publication date |
---|---|
PL355892A1 (en) | 2004-05-31 |
BG106854A (bg) | 2002-12-29 |
EA200200510A1 (ru) | 2002-10-31 |
WO2001040190A1 (en) | 2001-06-07 |
TR200201446T2 (tr) | 2002-11-21 |
EP1246804A1 (en) | 2002-10-09 |
NO20022558D0 (no) | 2002-05-29 |
IS6338A (is) | 2002-04-12 |
AU1048801A (en) | 2001-06-12 |
JP2003515592A (ja) | 2003-05-07 |
UY26454A1 (es) | 2001-07-31 |
CN1402711A (zh) | 2003-03-12 |
ECSP003792A (es) | 2002-04-23 |
KR20020058057A (ko) | 2002-07-12 |
IL149097A0 (en) | 2002-11-10 |
GT200000199A (es) | 2002-05-23 |
AP2002002531A0 (en) | 2002-06-30 |
CO5271716A1 (es) | 2003-04-30 |
CA2392979A1 (en) | 2001-06-07 |
MA26845A1 (fr) | 2004-12-20 |
MXPA02005354A (es) | 2002-12-11 |
TNSN00231A1 (fr) | 2002-05-30 |
OA12099A (en) | 2006-05-04 |
HUP0203521A2 (hu) | 2003-02-28 |
PE20010904A1 (es) | 2001-09-10 |
NO20022558L (no) | 2002-05-29 |
BR0015836A (pt) | 2002-08-06 |
EE200200277A (et) | 2003-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PA8506301A1 (es) | Cristal de 4- carboxamino- 1,2,3,4,- tetrahidroquinolina 2-sustituida | |
BR0111667A (pt) | Novos compostos | |
HN2002000275A (es) | Derivados de 1,8 naftiridina y su uso para el tratamiento de diabetes y trastornos relacionados | |
AR011069A1 (es) | Compuestos amidino, proceso para su preparacion, compuestos intermediarios, formulaciones farmaceuticas que los comprenden, y su uso en la fabricacion de un medicamento como inhibidor de la oxido nitrico sintasa inducible. | |
ES2090713T3 (es) | Sales organicas de n,n'-diacetil-cistina. | |
UY24555A1 (es) | Nuevos compuestos | |
GT199900102A (es) | Fenoxipropanolaminas, procedimiento para su preparacìon y composiciones farmacèuticasque las contienen. | |
MX9102501A (es) | Derivados de metano sulfonamida, composiciones farderivados de metanosulfonamida, composiciones farmaceuticas que los contienen y procedimiento para smaceuticas que los contienen y procedimiento para u preparacion. su preparacion. | |
ECSP055738A (es) | PROCESO ENANTIOSELECTIVO PARA LA PREPARACIÓN DE AMBOS ENANTIÓMEROS DE 10,11-DIHIDRO-10-HIDROXI-5H-DIBENZ-[b,f]-AZEPIN-5-CARBOXAMIDA Y SUS NUEVAS FORMAS DE CRISTAL | |
AR015349A1 (es) | Nuevas modificaciones cristalinas del 2-amino-4-(4-fluorbencilamino)-1-etoxicarbonil-aminobenceno y procedimiento para prepararlos, utilizacion de losmismas y medicamento que las contienen | |
HN2002000300A (es) | Nuevos derivados de piperazina | |
ES2157993T3 (es) | Benzoilguanidinas, su preparacion y su uso en medicamentos. | |
ES2134801T3 (es) | Monohidrato de hidrocloruro de tiagabina cristalina, su preparacion y su uso. | |
PA8586801A1 (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
NO934628L (no) | Retrovirus-protease-inhibitorer | |
HN2001000235A (es) | Derivados puentes de piperazina | |
ECSP034531A (es) | Derivados sustituidos de c-ciclohexilmetilamina | |
DK1051177T3 (da) | Steroide 3-O-Sulfamatderivater som inhibitorer af östronsulfatase | |
AR020563A1 (es) | Compuestos (poli)tia-alquinoicos y sus derivados, composiciones que los incluyen y su utilizacion | |
MX9303572A (es) | Inhibidores de proteasa del sindrome de inmunodeficiencia humana, procedimiento para su preparacion y formualcion farmaceutica que los contiene. | |
CR6398A (es) | Antagonistas de 5ht1 para terapia antidepresiva | |
ES2186989T3 (es) | Cristales de maltitol de formas especificas, compuestos cristalinos que los contienen y procedimientos para su preparacion. | |
PA8495001A1 (es) | Nuevas formas cristalinas de un antibiotico macrolido. | |
AR002017A1 (es) | Derivados de fenil-4-tiazoles substituidos, procedimiento para su preparacion, composiciones farmaceuticas que los contienen y derivados defenil-4-tiazoles substituidos empleados en dicho procedimiento. | |
BR9814495A (pt) | Composto, processo para prepará-lo, uso do mesmo, composição farmacêutica, e, processo |